FDA EXCLUSIVE: A Spotlight on Regulation in Antibacterial Drug Development



Superbugs and Superdrugs 2017

FDA Division of Anti-Infective Products Director, Sumathi Nambair, due to Present at Superbugs & Superdrugs 2017

Networking and learning with our peers is the secret to improving the drug development pipeline.

— Joint statement from Transcript Partners and Chemical Biology Ventures

LONDON, ENGLAND, UNITED KINGDOM, November 30, 2016 /EINPresswire.com/ — SMi Group are thrilled to have industry expert Sumathi Nambair, provide regulatory and compliance updates on FDA legislation in antibacterial drug development at the 19th annual 2017 Superbugs & Superdrugs show, returning to Central London on 20th and 21st March.

The long running event will once again gather a global audience of scientific leaders, government bodies and anti-infective specialists, providing a focal point to discuss the global action plan on antimicrobial resistance.
In her current role at the FDA, Dr. Nambiar provides regulatory oversight for anti-infective products, including antibacterial, antifungal, and antiparasitic drugs. Her keynote presentation will explore FDA development programmes and activities to facilitate antibiotic drug discovery.

SMi Group are also delighted to welcome the expertise of Xavier Duportet, CEO from Eligo Bioscience who has recently confirmed to speak. Following a €2M deal from leading microbiome investor, Seventure, the talk will offer progressive insight into sequence-specific antimicrobials for targeted eradication of carriage.

The notable speaker line-up on at Superbugs & Superdrugs 2017 will also include:

Richard Bax, Senior Partner, TranScrip
Lloyd Czaplewski, Director, Chemical Biology Ventures
Chris Houchens, Branch Chief, BARDA
James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline
Aileen Rubio, Head of Biology, Spero Therapeutics
David Williams, Chief Executive Officer, Discuva
Martin Everett, Chief Scientific Officer, ANTABIO SAS
Jean de Gunzburg, Scientific Director, Da Volterra
William J Weiss, Director, Pre-Clinical Services, UNT System College of Pharmacy

For those looking to attend there is currently a £400 saving available online ending on 30th November 2017. More information is available online at www.superbugssuperdrugs.com

Superbugs & Superdrugs 2017
20TH & 21ST March
Copthorne Tara Hotel, London, UK
http://www.superbugssuperdrugs.com

–end –

Contact Information:

For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For delegate inquiries contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk
For exhibition and sponsorship inquiries contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group
2078276000
email us here


Source: EIN Presswire

Reusing Electronic Health Records Data for Clinical Research

Providing services for reusing electronic health records data for clinical research is profitable and sustainable in Europe

GENEVA, SWITZERLAND, November 30, 2016 /EINPresswire.com/ — The results of a new study published in the International Journal of Medical Informatics suggest that the exploitation of a new technological platform which enables the reuse of hospital-based electronic health records (EHR) data for clinical research appears profitable and sustainable for service providers in Europe. This innovative platform was developed by the Electronic Health Records for Clinical Research (EHR4CR) project funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), under the Innovative Medicines Initiative (IMI).

Dr Danielle Dupont, Chief Scientific Officer at Data Mining International, the independent research agency which has led this study, stated: “For the first time, using advanced simulation modelling, our study shows that the exploitation of the EHR4CR platform appears profitable and sustainable for service providers, in addition to generating added value and benefits for all stakeholders. These new operational solutions being scaled up across Europe, further robust value assessment studies are warranted in real-world settings.”

Professor Dr Georges De Moor, Head, Medical Informatics and Statistics Department, Ghent University, explained: “By reusing EHR data for clinical research, protocol feasibility assessments, patient identification for recruitment in clinical trials, and clinical data exchange can be processed much faster, and with greater precision. Resulting from the EHR4CR and other successful European Research and Development projects, the secure InSite® platform services are now being deployed. They will significantly enhance and speed up the conduct of clinical trials.”

Professor Dr Dipak Kalra, President of the European Institute for Innovation through Health Data (I~HD) added: “The EHR4CR platform will transform the clinical research landscape by enabling the re-use of hospital-based EHR patient-level data. Given the governing role of the I˷HD in this emerging multi-stakeholder ecosystem, EHR4CR and equivalent service providers will be well-positioned and supported to deliver trustworthy innovative solutions to facilitate and accelerate the conduct of clinical trials.”

Advanced financial simulations have established that the exploitation of EHR4CR solutions appears profitable and sustainable for EHR4CR service providers, in addition to generating substantial added value for clinical trials sponsors. This business model confirms that tangible benefits and value will be delivered by this new technological platform, to all clinical research stakeholders, in a sustainable manner.

Reference: Dupont D, Beresniak A, Sundgren M, Schmidt A, Ainsworth J, Coorevits P, Karla D, Dewispelaere M, De Moor G. Business analysis for a sustainable, multi-stakeholder ecosystem for leveraging the Electronic Health Records for Clinical Research (EHR4CR) platform in Europe. International Journal of Medical Informatics 2017 (97): 341–352. http://dx.doi.org/10.1016/j.ijmedinf.2016.11.003

About Data Mining International: Data Mining International SA is an independent international research agency based in Geneva (Switzerland). Data Mining International is specialized in public health, data mining, big data analytics, business modelling innovation, advanced simulation modelling for decision-making, risk assessment, multi-criteria analyses, health technology assessment, eHealth applications, and development and validation of quality of life instruments. Data Mining International brings innovative solutions to the public and private sectors, including pharmaceutical and biotech industries, foods and cosmetics, public health organizations, academia, and other interest groups, stakeholders and decision-makers, across geographic boundaries.

Alina Juusti-Hawkes
Data Mining International SA
+358504627830
email us here


Source: EIN Presswire

MEDraysintell will launch its Market Essentials reports

The “Market Essentials” reports aim to provide accurate facts in a condensed document with real added value for the reader.

LOUVAIN-LA-NEUVE AND LALAYE, BELGIUM AND FRANCE, November 30, 2016 /EINPresswire.com/ — MEDraysintell plans to launch early 2017 two new “Market Essentials Reports” providing key facts on Nuclear Medicine and Proton Therapy to advice non-industry insiders on the potential for investments, merger and acquisitions (M&A), technology and market development existing in healthcare technologies using radiation for diagnosis and therapy.

Those “Market Essentials” Reports will be real assets for the healthcare industry or for the financial community (investors, investment bankers and M&A professionals) to support their audit and to make informed decisions with unbiased and factual intelligence from experts.

The “Market Essentials” reports aim to provide accurate facts in a condensed document with real added value for the reader. These documents are also intended to take the opposing view of the many recent articles and market reports written by non-experts which are regrettably providing misleading, outdated or inaccurate information on nuclear medicine as well as in particle therapy. MEDraysintell identified recent publications reporting about confusing information on a new potential Molybdenum-99 shortage, or unrealistic projections for the PET versus SPECT market, while not recognizing the growth in radiotherapeutics too often erroneously associated with brachytherapy. For the proton therapy industry, several market reviews presented inaccurate facts such as data about the installed base or ignoring several major equipment vendors even mentioning companies not linked to the proton therapy market.

The “Nuclear Medicine Market Essentials” and the “Proton Therapy Market Essentials” reports will include important insights on the market, key drivers, vendors, products of interest for the coming decade, as well as companies to monitor, mostly in tabulated forms with the most recent and precise figures and names.

MEDraysintell believes it is the right moment to publish such “Market Essentials” reports as both the nuclear medicine and proton therapy have entered an era of high potential for growth, involving new technologies and a high number of products close to being marketed or under advanced stage development. This business will trigger the interest of new investors as well as the conventional pharmaceutical industry to support these markets which are rising up to three times faster than the global healthcare market.

MEDraysintell has already supported numerous companies globally helping them to better understand these markets, and welcomes your requests for specific intelligence needs in these areas.

About MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy.

We offer the most comprehensive set of reports and directories, with over 1,800 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. www.medraysintell.com

Paul-Emmanuel Goethals and Richard Zimmermann
MEDraysintell
+32 491 080 968 and +33 6 82 80 06 00
email us here


Source: EIN Presswire

Targeting Cancer with Emerging Antisense Oligonucleotide Drugs and Nano Medicines. Clinical Results Unveiled at RNA 2017



RNA Therapeutics 2017

RNA Therapeutics returns to Central London on 22nd & 23rd February 2017 featuring a spotlight on RNA used to in Cancer therapy

For cancer diseases, RNAi will provide the specificity that was missed by standard chemotherapy, immune-oncology will supress immune resistance

— Silenseed

LONDON, ENGLAND, UNITED KINGDOM, November 30, 2016 /EINPresswire.com/ — Due to significant investment and promising results in early phase clinical trials for chronic and rare diseases, reports have predicted the DNA and RNA therapeutics market to reach $1.2 billion by 2020. Of the 700 DNA and RNA therapeutics that are in the drug development pipeline, nearly 35% are targeting oncology.* Source http://bit.ly/1RAivXk

Hear more on cancer therapeutics next February when SMi’s 8TH annual 2017 conference on RNA Therapeutics returns to London.

Featured presentations include:

INTRAVENOUSLY INJECTABLE RNA NANOMEDICINES AS CANCER VACCINES: CASE STUDY WITH RNA-LIPOPLEXES:

Heinrich Haas, RNA Formulation and Drug Development Vice President at BioNTech AG will provide new updates on the development of nucleic acid based nanomedicines. The talk will explore mRNA for cancer vaccination with detailed insight into formulation development and preclinical proof-of concept for RNA-lipoplex formulations. GMP manufacturing and clinical testing of RNA-lipoplex products will also be discussed.

THERAPEUTIC ANTISENSE OLIGONUCLEOTIDES IN ONCOLOGY:

A big pharma update on clinical trials in oncology as Mark Edbrooke, Senior Principal Scientist from AstraZeneca, looks at the progress of emerging antisense oligonucleotide drugs and drug delivery methods to target "un-druggable" sites.

INDIVIDUALISED MRNA-BASED CANCER IMMUNOTHERAPY:

Hear how BioNTech are driving progress in cancer immunotherapy through case study results into the first clinical experience with mRNAs in individualised cancer immunotherapy. Vice President for RNA Biochemistry & Manufacturing, Andreas Kuhn, will give insight into key topics surrounding: the optimisation of mRNA for therapeutic applications; GMP manufacturing of mRNA; and the IVAC MUTANOME concept.

Further information is available online at www.therapeutics-rna.com

8th Annual Event: RNA Therapeutics 2017
Conference: 22nd & 23rd Feb | Interactive workshop: 21st Feb
Copthorne Tara Hotel, Kensington, London, UK

— end —

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit http://www.therapeutics-rna.com or contact Fateja Begum on
Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /
Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group
2078276000
email us here


Source: EIN Presswire

JAMES BURKE CONNECTIONS APP Kickstarter campaign launches

James Burke

Kickstarter Logo

Hex interface

James Burke is renowned for his ability to find intriguing connections among ideas. With this app, you too can think like James.

Everything is connected to everything else, including you too, of course.

— James Burke

HARRISONBURG, VIRGINIA, UNITED STATES, November 23, 2016 /EINPresswire.com/ — FOR IMMEDIATE RELEASE November 29, 2016
JAMES BURKE CONNECTIONS APP

Knowledge Discoveries LLC has announced a Kickstarter Campaign to fund development of the James Burke Connections App. James Burke is renowned for his ability to find intriguing connections among ideas. With this app, you too can think like James.

The App makes a great holiday gift for friends and family, teachers and students, nieces and nephews; anyone who could benefit from thinking in new and innovative ways.

ABOUT JAMES BURKE

James Burke has been referred to as one of the most intriguing minds in the Western world (Washington Post, 1994). The hallmark of his thinking style is to identify the connections among seemingly unrelated events. Using a network of links and nodes and highlighting the inter-connections among them, James' unique gift is the ability to see relations among people and ideas where others have not.

He has created dozens of books, articles, and television series around the notion that, as he says so famously, "Everything is connected to everything else, including you too, of course."

ABOUT THE JAMES BURKE CONNECTIONS APP

The app combines the unexpected connections of Burke’s K-web with the rich and extensive content housed in Wikipedia to create a new type of knowledge tool. With the App, you can Explore, Discover, and Present new ideas, connections, and knowledge in ways never before possible. With the App, you can put the power of connected thinking to work for you, for school projects, business presentations, or ideas you want to develop. Click here to see the David McRaney interview.

The Kickstarter Campaign is open now and is accepting contributions in amounts from $5 to $1000 with rewards available for JB Noodlers, JB Wikipedia Editors, JB Teacher Ambassadors, along with signed James Burke memorabilia (books, DVDs). The Campaign runs until January 2, 2017.

See the Kickstarter site at https://www.kickstarter.com/projects/504632459/james-burke-connections-app. A functional prototype of the App is available at the site.

James is available for interviews (phone, Skype). Media inquiries should be directed to RichIngram@KnowledgeDiscoveries.com (540 209-0520).

@KnoDiscovery #JBConnectionsApp @Thejamesburke #creativity

Rich Ingram
Knowledge Discoveries LLC
5402090520
email us here

James Burke Connections App Kickstarter campaign introduction


Source: EIN Presswire

Atrial Fibrillation Patients Are at Increased Risk of Dementia, Regardless of Anticoagulation Use, New Study Finds

Atrial fibrillation patients are at higher risk of developing all forms of dementia compared to patients without atrial fibrillation, according to new study.

“We are initiating a series of new studies that are aimed to understand what treatments may reduce the risk of developing dementia in atrial fibrillation patients.”

— Jared Bunch, MD, Intermountain Medical Center Heart Institute.

SALT LAKE CITY , UT, USA , November 29, 2016 /EINPresswire.com/ — Atrial fibrillation patients who use the drug warfarin to prevent harmful blood clots from forming in their hearts to lower risk of stroke are at higher risk of developing dementia than patients who use warfarin for non-atrial fibrillation conditions, according to a new study from the Intermountain Medical Center Heart Institute.

Atrial fibrillation is an abnormal heart rhythm that raises the risk of small clots forming in the heart and leading to a stroke. Warfarin is the most common anticoagulant drug used worldwide to lower risk of the harmful clots from forming and causing stroke.

For the study, Intermountain researchers looked at more than 6,000 patients who had no history of dementia and were chronically anticoagulated using warfarin for any indication – not just atrial fibrillation. The patients were then divided into two groups: Those with atrial fibrillation who were using warfarin, and those using warfarin who did not have atrial fibrillation.

After adjusting for multiple variations, patients with atrial fibrillation were two to three times more likely to develop dementia compared to the patients who were on warfarin, but did not have a diagnosis of atrial fibrillation.

“Atrial fibrillation patients are at higher risk of developing all forms of dementia compared to patients without atrial fibrillation. Warfarin is used to lower risk of stroke in patients with atrial fibrillation, but when the blood levels of the drug are erratic it contributes to the dementia risk. This dementia risk is observed in people with and without atrial fibrillation that are exposed to long-term warfarin treatment” said Jared Bunch, MD, lead author of the study and director of electrophysiology at the Intermountain Medical Center Heart Institute in Salt Lake City.

“Even when we consider the influence of warfarin on dementia risk, the presence of atrial fibrillation conveys additional risk of dementia. This suggests that they way we manage the abnormal heart rhythm, beyond just the practice of preventing blood clots through warfarin, may be a way we can further lower the risk of all forms of dementia, including Alzheimers disease, in patients with atrial fibrillation,” Dr. Bunch added.

Results of the study were presented during the American Heart Association's 2016 Scientific Sessions in New Orleans on Nov. 15.

Seven years ago, researchers from the Intermountain Medical Center Heart Institute found that patients with atrial fibrillation had much higher rates of all forms of dementia, including Alzheimer’s disease. Since then, researchers have continued to explore the association between atrial fibrillation and dementia in an effort to better understand and identify ways to prevent dementia in heart patients.

“Further research is needed to identify the many complex mechanisms that link atrial fibrillation to dementia,” said Dr. Bunch. “We are initiating a series of new studies that are aimed to understand what treatments may reduce the risk of developing dementia in atrial fibrillation patients.”

Other members of the Intermountain Medical Center Heart Institute team include Kevin Graves, BS; Heidi T. May, PhD; Tami L. Bair, RN; Victoria Jacobs, PhD; Brian G. Crandall, MD; Michael Cutler, MD; Jeffrey S. Osborn, MD; Charles Mallender, MD; John D. Day, MD; and Peter Weiss, MD.

Intermountain Medical Center is the flagship facility for the Intermountain Healthcare system, which is based in Salt Lake City.

Jess Gomez
Intermountain Medical Center
801-507-7455
email us here

Atrial Fibrillation Research from AHA 2016 Scientific Sessions


Source: EIN Presswire

Global Aerospace & Defense Fluid Conveyance Systems Market Expected to Reach $3.9 Billion in 2021 During 2016 to 2021



The Publisher, a Global Market Intelligence Firm

An Extensive Market Research Report from Stratview Research Includes Trends, Forecasts, Competitive Analysis and Strategic Growth Opportunities.

DETROIT, MI, USA, November 29, 2016 /EINPresswire.com/ — Stratview Research announces the launch of a new research report on Global Aerospace & Defense Fluid Conveyance Systems Market by Aircraft Type (Commercial, Regional, General Aviation, Helicopter, and Military Aircraft), by Application (Fuel, Air, and Hydraulic), by Product Type (Hoses & Tubes, Low Pressure Ducts, and High Pressure Ducts), by Materials Type (Titanium & Alloys, Stainless Steel & Alloys, Composites, and Others), and by Region (North America, Europe, Asia-Pacific, and RoW), Trend, Forecast, Competitive Analysis, and Growth Opportunity: 2016 – 2021.
This strategic report, from Stratview Research, studies the global fluid conveyance systems market in the aerospace & defense industry over the period 2010 to 2021. The report provides detailed insights on the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.

The Global Fluid Conveyance Systems Market in the Aerospace & Defense Industry: Highlights

As per Stratview Research, the global aerospace & defense fluid conveyance systems market offers a healthy growth opportunity of 5.8% CAGR during the forecast period of 2016 to 2021 and reach $3.9 billion in 2021. The author of the report stated that increasing revenue per passenger kilometer due to growing worldwide economy and passenger traffic, increasing commercial and regional aircraft deliveries, increasing share of wide body aircraft in aircraft deliveries, increasing commercial aircraft fleet size, increasing demand of lightweight hoses and ducting and development of efficient engines with high thrust are some of the major drivers of the global aerospace & defense fluid conveyance systems market.

High pressure duct was estimated to be the largest product segment in the global aerospace & defense fluid conveyance systems market in 2015, followed by hoses & tubes and low pressure ducts.
In terms of materials, Nickel & alloys dominate the global market followed by teflon, composites and titanium & alloys. Composites based systems are likely to experience the fastest growth of 7.8% CAGR from 2016 to 2021 owing to continuous gain in low pressure applications.
The author of the report cited that commercial aircraft is expected to remain the largest segment for fluid conveyance during the forecast period. Also, the segment is likely to witness the fastest growth over the next five years as well; whereas military aircraft, the second largest segment, is expected to register the slowest growth for the same period.
North America was the most dominant regional market for fluid conveyance systems in aerospace & defense industry in 2015, followed by Europe and Asia-Pacific. Asia-Pacific region experienced the fastest growth over the last five years for the market and is expected to continue to do so over the next five years as well.

As per Stratview Research, the global aerospace & defense fluid conveyance systems market is moderately consolidated with more than two dozen players active in the market. Top 5 players (Eaton Corporation, Senior Plc, Arrowhead Products, Unison Industries, and Zodiac Aerospace) captured more than 50% of the market in 2015.
Focus on commercial aircraft, collaboration with OEMs for upcoming aircraft, development of innovative lightweight products, and focus on North America & Asia Pacific are some of the key success factors in the global aerospace & defense fluid conveyance systems market.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights on the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

• Market structure: Overview, industry life cycle analysis, supply chain analysis.
• Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
• Market trend and forecast analysis.
• Market segment trend and forecast.
• Competitive landscape and dynamics: Market share, product portfolio, product launches, etc.
• Attractive market segments and associated growth opportunities.
• Emerging trends.
• Strategic growth opportunities for the existing and new players.
• Key success factors.

Stratview Research has number of high value market reports in the global aerospace & defense industry. Please refer to the following link to browse through our reports:
Click Here for Other Reports from Stratview Research in the Aerospace & Defense Industry

About Stratview Research

Stratview Research is a global market intelligence firm providing wide range of services including syndicated market reports, custom research and sourcing intelligence across industries, such as Advanced Materials, Aerospace & Defense, Automotive & Mass Transportation, Consumer Goods, Construction & Equipment, Electronics and Semiconductors, Energy & Utility, Healthcare & Life Sciences, and Oil & Gas.
We have a strong team of industry veterans and analysts with an extensive experience in executing custom research projects for mid-sized to Fortune 500 companies, in the areas of Market Assessment, Opportunity Screening, Competitive Intelligence, Due Diligence, Target Screening, Market Entry Strategy, Go to Market Strategy, and Voice of Customer studies.
Stratview Research is a trusted brand globally, providing high quality research and strategic insights that help companies worldwide in effective decision making.
For any enquiries,

Contact:
Ritesh Gandecha
Stratview Research
E-mail: sales@stratviewresearch.com
Direct: 1-313-307-4176
Feel free to drop an enquiry with us in the below page and our team will get back to you very soon:
http://www.stratviewresearch.com/register.php

Ritesh Gandecha
+1-313-307-4176
email us here
Stratview Research


Source: EIN Presswire

Kepley BioSystems Chosen as Finalist in NC Idea Fall 2016 Grant Cycle

Dr. Anthony Dellinger, President of Kepley BioSystems and Murphy, his trusted fishing companion, prepare for a day on the water wielding a bucket of the KBI patent pending synthetic fish bait, OrganoBait.

NC Idea’s selected finalist Kepley BioSystems has invented OrganoBait, an alternative fishing technology that will stem the use of forage fish in recreational baiting industries worldwide.

The KBI Logo

KBI has invented an alternative bait for recreational anglers that is being recognized as finalist in the prestigious 2016 NC Idea seed fund competition.

GREENSBORO, NORTH CAROLINA, U.S.A., November 28, 2016 /EINPresswire.com/ — November 28, Greensboro, NC – Kepley BioSystems (KBI) announced today that the company has been selected as a finalist among ten other North Carolina start-ups vying for one of five $50,000 NC Idea grants totaling $250,000. Each firm will present to a blue-ribbon panel of experts on December 2, as they compete in the 22nd NC Idea Grant Cycle, underlining the prominence of North Carolina as a center of excellence dedicated to innovation and entrepreneurship.

Kepley BioSystems is an academically-driven life sciences company that has discovered and developed patent-pending attractants for use in commercial and recreational fishing as a means to conserve wild fish. Also called baitfish, these nutritional dynamos comprise an endangered and vital link in the food web sustaining not only the rest of the fish, marine mammals and seabirds, but also increasingly consumed in aquaculture, agriculture, nutritional supplements and domestic pet food and as bait for commercial and recreational fishing. The KBI product branded as OrganoBait™ is synthetically formulated to release a molecular symphony of primal, olfactory stimulants calibrated and shown to elicit foraging and feeding behaviors in crustaceans and fish, without fish or animal ingredients.

About NC Idea

NC IDEA is a private foundation committed to supporting business innovation and economic advancement in North Carolina and serves as a catalyst for young, high-growth companies. Today, the organization fulfills this mission through four initiatives. The Ecosystem Partner Grant program funds organizations across the state that executes creative programs to support entrepreneurs. Over the last decade, the Seed Grant program has awarded over $4.5M to 109 high-growth companies across the state. Since 2011, more than 100 companies have participated in the Groundwork Labs startup program. SoarTriangle, a program founded in 2012 to address the proven funding gap for female entrepreneurs, formally became a foundation program in August 2016.

For more information, visit: https://www.ncidea.org

About Kepley BioSystems

Kepley BioSystems originated at the Joint School of Nanoscience and Nanoengineering (JSNN), North Carolina A&T State University and The University of North Carolina at Greensboro; the company is now located at the Gateway University Research Park proximal to JSNN. Kepley BioSystems is a proud National Science Foundation (NSF) research grant recipient and an academically-driven company led by Professor Christopher Kepley and Dr. Anthony Dellinger, a recent graduate, working in collaboration with lead inventor Terry E. Brady, located on the Caribbean island of Anguilla, British West Indies.

For more information, visit: http://www.kepleybiosystems.com

Anthony L. Dellinger, PhD
Kepley BioSystems Incorporated
336-217-5163
email us here


Source: EIN Presswire

Facebook presents mobile solutions for patient engagement and personalised marketing

The 9th Social Media in the Pharmaceutical Industry event will take place in January 2017

Sachin Nanavati, Facebook Health

Facebook to explore

One key shift is how rapidly people have moved to mobile. And in part thanks to this shift, we've seen people increasingly leverage platforms like Facebook as a central place for health-conversation.

— Sachin Nanavati, Facebook Health

LONDON, ENGLAND, UNITED KINGDOM, November 28, 2016 /EINPresswire.com/ — Sachin Nanavati, Manager of Global Marketing Solutions at social media giant Facebook, joins the expert speaker line-up for the 9th Social Media in the Pharmaceutical Industry which takes place on the 18th and 19th of January 2017 in London.

With a focus on leveraging the Facebook platform to achieve personalised marketing at scale, Sachin’s keynote presentation will explore the advantages of using Facebook as a central place for evidence-based healthcare discussions through full-funnel marketing so as to reach and engage the right patients with the right message at the right time. He will also discuss creative best practices for branded and unbranded campaigns.

In a recent interview with SMi Group, Sachin talked about how shifts in consumer behaviour have brought forth an avenue for patients and HCPs to engage more on Facebook.

“One key shift is how rapidly people have moved to mobile. And in part thanks to this shift, we've seen people increasingly leverage platforms like Facebook as a central place for health-conversation. In fact, there are 6 million health related-groups on Facebook with over 70 million members. This level of health engagement presents a massive opportunity for healthcare brands to contextualize the right message to the right patient at the right time on Facebook – particularly on mobile. It's a content discovery platform where nearly 1.8 billion people come to engage with the people and brands that matter most to them in their lives.

It's really exciting to think about this from a patient perspective and the possibility that a more open and connected world has to improve health outcomes. Facebook is a safe and powerful way for marketers to engage patients at scale with contextualized evidence-based messages to help them make the best decisions for their health. It’s also powerful channel for vibrant patient communities where people can safely connect, share and meet other people like them. Patient communities like ActuallySheCan and SaveYourBreath are great examples of brands building meaningful platforms on Facebook that go beyond the pill.”

The full interview with Sachin is available to view at the Download Centre on www.social-media-pharma.com/EIN.

Sachin joins an line-up of expert healthcare practitioners and marketers who will discuss and debate the latest trends in e-healthcare, technologies, and top tricks of the trade to maximise digital strategy. Other speakers include CREATION, Lundbeck, MHRA, Merck, Pfizer, GE Healthcare Life Sciences, AbbVie, Leo Pharma, and more

For more updates on the conference, follow SMi Group on @smipharm and join the conversation using #pharmasocialmedia on Twitter.

9th Social Media in the Pharmaceutical Industry
18 & 19 January 2017
Holiday Inn Kensington Forum, London, UK
http://www.social-media-pharma.com/EIN

—end —

Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Matthew Apps at mapps@smi-online.co.uk. For media queries please contact Honey de Gracia at hdegracia@smi-online.co.uk.

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Honey de Gracia
SMi Group Ltd
+44 (0)20 7827 6102
email us here


Source: EIN Presswire

Most Modern Infrastructure Available for Laparoscopic and Robotic Surgery Training

Dr R K Mishra

World Laparoscopy Hospital

Robotic Surgery Training at World Laparoscopy Hospital

World Laparoscopy Hospital is a prestigious training center for the excellent quality of education in laparoscopic and robotic surgical procedures.

World Laparoscopy Hospital is The Premier Institute of Minimal Access Surgery

— Dr R K Mishra

GURGAON, NCR DELHI, INDIA, November 28, 2016 /EINPresswire.com/ — Although laparoscopic surgery has been applied in practice by multiple surgical specialties for nearly two decades, the penetration of laparoscopic surgery training institute in the Asian Countries remains less than ideal. In today’s world, surgical specialization that fail to update their advanced minimal access surgical learning practices often struggle with professional growth or productivity. As a result, leading hospitals are abandoning traditional methods of surgery in favour of more effective solutions.

It may be questioned why laparoscopy is not more widely practiced and the answer is that formal laparoscopic training is not being offered in most residency training programs. In these circumstances institutions like World Laparoscopy Hospital has great role in offering technology innovation that engage talent and improve performance by providing hands on laparoscopic and robotic surgery training to surgeons and gynaecologists.

One-third of medical colleges are increasing their budget for learning and development of minimal access surgery. 41 percent of hospital describe their culture as “Day Care Surgery” and searching for skilled laparoscopic surgeon and gynaecologist. Only 10 percent of medical institutions are leveraging laparoscopic surgery learning solutions and have good infrastructure to provide hands on minimal access surgical skill. 59 percent of newly trained medical postgraduate surgeons and gynaecologists are leveraging learning activities in specialized institutes and searching a good institute to develop their fundamental minimal access surgical skill.

Medical institutes all over world are facing several critical pressures, including a short supply of skilled laparoscopic or robotic surgeons, gynaecologist and urologist. In these difficult situation where developing surgical skill of surgeon is required World Laparoscopy Hospital is prioritizing the Individual need of learning laparoscopic surgery. Finding and keeping talented skilled minimal access surgeon is no longer an HR challenge but a strategic healthcare priority. There is need of institution like World Laparoscopy Hospital which provide a new scientifically proven mechanism for teaching laparoscopic and robotic surgery. This super specialized institute provide a service for minimal access surgeon from all over the world where they can adapt to the needs of a changing workforce and align closely with objectives of developing skill. For many conventional medical institute, an updated learning and development process is long overdue and WLH is trying to fulfil these objective.

Trends in Laparoscopic Training and Recommendations:

For those who may have only gained basic laparoscopic skills in residency and for those who graduated before any training was available, gaining expertise in laparoscopy after residency is a difficult task. World Laparoscopy hospital is trying to fill up these gap and imparting Hands On Skill to surgeons and Gynaecologist. Although learning is one of the most mature areas of continued medical institution, it is also one of the most innovative. With recent technology advancements and the rapid adoption of scientific collaboration, learning and development has come a long way. Yet making a decision to improve a minimal access surgery training program and invest in a learning management solution is often a daunting challenge. Five key trends and best practices that medical institution should consider include the use of virtual reality simulation technology, adoption of practical learning skill lab learning tools, use of adaptive skill based learning principles, and the ability to measure effectiveness of these training programmes.

Unfortunately, if surgeons flock to advanced laparoscopic surgery due to market pressures and patient demand without adequate training in laparoscopy itself, the likelihood of convincing such surgeons of the benefits of, and need for, laparoscopy training is low. Hands On laparoscopic surgery training given by World Laparoscopy Hospital is a methodology that breaks traditional models and allows surgeons and gynecologists to learn at their own pace. It has gained popularity with educational institutions, referred to as “adaptive teaching,” where a teacher will gather information on individual students to learn what they need to do to improve their learning. Minimal access surgical skill.

In the past scenario medical colleges had limited technology choices for learning and development of surgical skill, but today there are new solutions emerging every month. Organizations should consider providers with innovative capabilities like World Laparoscopy Hospital and also understand the importance of measuring the effectiveness of learning activities. Even if the surgeon’s laparoscopy training limited or only for a restricted set of operative procedures, the basic skills of laparoscopy, just as with open surgery, will benefit the surgeon in all regards, including in performing advanced minimal access surgery.

Due to one of the most advanced infrastructure available for laparoscopic and robotic surgery training available on this planet, World Laparoscopy Hospital is a prestigious training center in the World recognized nationally and internationally for the excellent quality of education in laparoscopic procedures. This institute provide complete hands on training to surgeon and gynecologist during their Fellowship and Diploma in Minimal Access Surgery Program.

Regular courses are being conducted in laparoscopic Surgery for General Surgeons, Gastroenterologists, paediatric. Surgeons, Cardio-Thoracic Surgeons, Gynaecologists & Urologists for the past 17 years at WLH. More than 7000 Surgeons and gynecologists have benefited in the art of Laparoscopy in India and abroad.

Rajneesh Mishra
World Laparoscopy Hospital
9811416838
email us here

World Laparoscopy Hospital Laparoscopic and Robotic Surgery Training Program


Source: EIN Presswire